Anavex Life Sciences (AVXL) Total Liabilities (2011 - 2025)
Anavex Life Sciences (AVXL) posted Total Liabilities of $6.4 million for Q4 2025, down 28.78% sequentially from $8.9 million in Q3 2025, and down 51.47% YoY from $13.1 million in Q4 2024.
Anavex Life Sciences (AVXL) Total Liabilities (2011 - 2025) Analysis & Trends
Anavex Life Sciences has reported Total Liabilities for 15 years, with the latest figure at $6.4 million in Q4 2025.
- Quarterly Total Liabilities fell 51.47% year-over-year to $6.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.4 million (down 51.47% YoY) and the FY2025 annual result came in at $8.9 million, down 41.54% from the prior year.
- Total Liabilities slipped to $6.4 million in Q4 2025 per AVXL's latest filing, from $8.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $160.3 million in Q1 2022 and troughed at $6.4 million in Q4 2025.
- A 5-year average of $37.4 million and a median of $12.5 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 1627.68% in 2022, then sank 93.1% in 2023.
- Over 5 years, Total Liabilities stood at $156.9 million in 2021, then sank by 91.56% to $13.2 million in 2022, then decreased by 5.68% to $12.5 million in 2023, then advanced by 5.07% to $13.1 million in 2024, then slumped by 51.47% to $6.4 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $6.4 million, $8.9 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 6.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.37 Mn |
| Sep 30, 2025 | 8.95 Mn |
| Jun 30, 2025 | 11.47 Mn |
| Mar 31, 2025 | 17.38 Mn |
| Dec 31, 2024 | 13.13 Mn |
| Sep 30, 2024 | 15.30 Mn |
| Jun 30, 2024 | 11.75 Mn |
| Mar 31, 2024 | 9.56 Mn |
| Dec 31, 2023 | 12.50 Mn |
| Sep 30, 2023 | 12.53 Mn |
| Jun 30, 2023 | 11.06 Mn |
| Mar 31, 2023 | 14.02 Mn |
| Dec 31, 2022 | 13.25 Mn |
| Sep 30, 2022 | 10.21 Mn |
| Jun 30, 2022 | 160.22 Mn |
| Mar 31, 2022 | 160.28 Mn |
| Dec 31, 2021 | 156.90 Mn |
| Sep 30, 2021 | 10.80 Mn |
| Jun 30, 2021 | 9.27 Mn |
| Mar 31, 2021 | 83.57 Mn |